CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Home Pulse Oximetry MonitoringWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Utilizing Home Pulse Oximetry for Patients With COVID-19 To Monitor Disease Progression

The purpose of this study is to investigate the use of home pulse oximetry monitoring in patients with COVID-19 to trend disease progression and identify need for hospitalization.

NCT04373161 Sars-CoV2 COVID-19 COVID Device: Home Pulse Oximetry Monitoring

Primary Outcomes

Description: The primary outcome is the relative risk of hospitalization in COVID-19 patients with resting home pulse oximeter SpO2 below 92%.

Measure: Hospitalization in COVID-19 patients with low home SpO2

Time: 7 days after enrollment

Secondary Outcomes

Description: The purpose of this outcome is to determine if home pulse oximetry readings abruptly drop, gradually decline, or stay level in patients with COVID-19

Measure: Trend in resting home pulse oximetry readings

Time: 7 days after enrollment

Description: This will evaluate if there is a correlation between the time of day with SpO2 readings below 92 percent in patients with suspected COVID-19.

Measure: Timing of SpO2 <92%

Time: 7 days after enrollment

Description: The goal of this outcome is to see if patients enrolled in the study are reassured by use of home pulse oximeter monitoring and if this device prevents subsequent ED visits by patients

Measure: Home pulse oximeter use effect on subsequent ED visits

Time: 7 days after enrollment

Description: To see if patients who return to the ED and end up hospitalized did so for incidental finding of low home pulse oximetry or if it was for worsening symptoms

Measure: Reason for return to the Emergency Department

Time: 7 days after enrollment

Description: The study will assess development of morbidity defined as intensive care unit admission, acute respiratory distress syndrome, and/or septic shock in patients with SpO2 <92%

Measure: Hospitalization outcome - morbidity

Time: Up to 21 days after enrollment

Description: The study will assess mortality defined as death after admission to the hospital in patients with SpO2 <92%

Measure: Hospitalization outcome - mortality

Time: Up to 21 days after enrollment

Description: The study will measure median length of stay in patients with COVID-19 that are hospitalized on subsequent return to the ED.

Measure: Median Length of Stay

Time: Up to 21 days after enrollment


No related HPO nodes (Using clinical trials)